Apnimed to Present New OHS Prevalence Findings at ERS Congress 2024

CAMBRIDGE, Mass., Sept. 4, 2024 -- Apnimed, Inc., a company in the clinical trial phase focusing on developing and commercializing new oral treatments for obstructive sleep apnea (OSA) and other sleep disorders, announced its participation in the European Respiratory Society Congress (ERS) from September 7-11, 2024, in Vienna, Austria. Apnimed will present a poster detailing the prevalence and characteristics of patients with obesity hypoventilation syndrome (OHS) based on data from a recent clinical trial the company sponsored.

OHS is characterized by a combination of sleep-disordered breathing, obesity, and daytime hypercapnia, which is an elevated level of carbon dioxide in the blood. The condition represents a substantial clinical challenge with significant unmet patient needs.

Details of Apnimed's ERS 2024 Presentation:
Poster: PA875
Session: 82 – "Early detection of obesity hypoventilation syndrome: prevalence and physiological differences within a cohort of obese patients"
Date and Time: Sunday, September 8, 8 – 9:30 AM CEST
Location: RX Wien GmbH, PS-8 in the poster area
Presenter: Elisa Perger, MD, Istituto Auxologico Italiano IRCCS, Milan, School of Medicine and Surgery, University of Milano Bicocca

About Apnimed:
Apnimed is a pharmaceutical enterprise in the clinical development stage, aiming to revolutionize the treatment landscape for sleep apnea through innovative oral medications. Their principal program, AD109, is designed to enhance the neurologic control of upper airway muscles, ensuring the airway remains open during sleep. Based in Cambridge, Massachusetts, Apnimed is expanding its portfolio to include a range of new pharmacologic treatments for sleep apnea and other related disorders. The company is also involved in a joint venture with Shionogi & Co., Ltd., known as Shionogi-Apnimed Sleep Science, LLC, to further develop these therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!